Morgan Stanley maintains a bicara (Bicax) classification after a ficerafusp alfa trial update

On May 23, Judah from Morgan Stanley maintained a purchase rating on Bicara Therapics Inc. (Nasdaq:BCAX) Maintaining the target price at $ 36.

This comes after the company released its temporary data from the 1/1B experience of Ficerafusp alfa, which is the main origin of the company and antibodies to the duo in the first category.

An close to a scientist in a laboratory conducting tests on the human immunological glyculin G1.

Bicara Therapeutics Inc. (NASDAQ: BCAX) is a biological pharmaceutical company for clinical stage that develops antibodies with innovative functional functional function. Ficerafusp alfa is tested to enhance the penetration of the tumor and overcome the microscopic environment of the immunosuppressive tumor, which limits the effectiveness of historically treatment in solid tumors.

Modern data from the study of the 1/1B stage showed promising results in the treatment of negative HPV patients who have heinous cell cancer in the head and neck. The analyst has highlighted that the experiment reported that a total survival of a total of 20 months, including a full response rate of 18-21 %. Frommer believes that this is a significant improvement compared to standard care, indicating that the approval of ficerafusp alfa can be a mutation in a difficult treatment area.

While we acknowledge the BCAX capabilities as an investment, our conviction is to believe that some of the artificial intelligence shares have a greater promise to provide higher and limited negative risks. If you are looking for a more promising IQ stock of BCAX and has 100x capabilities, check our report on The cheapest inventory of artificial intelligence.

Read the following: 11 promising new technology shares according to analysts and 12 best arrows growth to buy and keep them in the long run.

Detection: Nothing.